Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MPO | P05164 | 5/20 | 0.75 |
| ▸ | HTR2A | P28223 | 8/20 | 0.63 |
| ▸ | HTR2C | P28335 | 6/20 | 0.63 |
| ▸ | HRH1 | P35367 | 1/20 | 0.54 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.54 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.54 |
| ▸ | HTR2B | P41595 | 1/20 | 0.54 |
| ▸ | HTR6 | P50406 | 1/20 | 0.54 |
| ▸ | CA2 | P00918 | 2/20 | 0.51 |
| ▸ | CA12 | O43570 | 1/20 | 0.51 |
| ▸ | CA1 | P00915 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25809436 | 0.90 | MPO (0.75) | MPOHTR2AHTR2CHRH1OPRM1 | |
| SCHEMBL17287296 | 0.89 | HTR2A (0.67) | MPOHTR2AHTR2CHRH1OPRM1 | |
| SCHEMBL29633027 | 0.89 | HTR2A (0.67) | MPOHTR2AHTR2CHRH1OPRM1 | |
| SCHEMBL29633101 | 0.89 | HTR2A (0.67) | MPOHTR2AHTR2CHRH1OPRM1 | |
| SCHEMBL25394698 | 0.83 | MPO (0.72) | MPOHTR2AHTR2CHRH1OPRM1 | |
| SCHEMBL30200756 | 0.83 | MPO (0.72) | MPOHTR2AHTR2CHRH1OPRM1 | |
| SCHEMBL25397520 | 0.83 | MPO (0.72) | MPOHTR2AHTR2CHRH1OPRM1 | |
| SCHEMBL24163036 | 0.82 | MPO (0.71) | MPOHTR2AHTR2CHRH1OPRM1 | |
| SCHEMBL25398887 | 0.82 | MPO (0.71) | MPOHTR2AHTR2CHRH1OPRM1 | |
| SCHEMBL24163070 | 0.82 | MPO (0.71) | MPOHTR2AHTR2CHRH1OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4680236-A2 | 3-ALKYLAMINE INDOLE ACTIVATORS OF SEROTONIN RECEPTORS | ATAI Therapeutics, Inc. (US) | 2026-01-21 | — | — | EP | disclosed |
| EP-4637735-A1 | DIMETHOXYPHENYL HETEROAROMATIC ALKYLAMINE ACTIVATORS OF SEROTONIN RECEPTORS | ATAI Therapeutics, Inc. (US) | 2025-10-29 | — | — | EP | disclosed |
| US-20250282712-A1 | DIMETHOXYPHENYLALKYLAMINE ACTIVATORS OF SEROTONIN RECEPTORS | ATAI THERAPEUTICS INC (US) | 2025-09-11 | — | — | US | disclosed |
| US-20250282708-A1 | AMINOTETRALINE ACTIVATORS OF SEROTONIN RECEPTORS | ATAI THERAPEUTICS, INC. (US) | 2025-09-11 | — | — | US | disclosed |
| US-12351537-B2 | Dimethoxyphenylalkylamine activators of serotonin receptors | ATAI THERAPEUTICS, INC. (US) | 2025-07-08 | — | — | US | disclosed |
| US-12344570-B2 | Aminotetraline activators of serotonin receptors | ATAI THERAPEUTICS, INC. (US) | 2025-07-01 | — | — | US | disclosed |
| WO-2025122979-A1 | COMPOUNDS FOR SEROTONIN RECEPTOR ACTIVATION AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME | ATAI THERAPEUTICS, INC. (US) | 2025-06-12 | — | — | WO | disclosed |
| EP-4457203-A1 | AMINOTETRALINE ACTIVATORS OF SEROTONIN RECEPTORS | ATAI Therapeutics, Inc. (US) | 2024-11-06 | — | — | EP | disclosed |
| WO-2024192150-A2 | 3-ALKYLAMINE INDOLE ACTIVATORS OF SEROTONIN RECEPTORS | Atai Therapeutics Inc. (US) | 2024-09-19 | — | — | WO | disclosed |
| US-20240300885-A1 | AMINOTETRALINE ACTIVATORS OF SEROTONIN RECEPTORS | ATAI Life Sciences AG (DE) | 2024-09-12 | — | — | US | disclosed |
| US-20240294461-A1 | DIMETHOXYPHENYLALKYLAMINE ACTIVATORS OF SEROTONIN RECEPTORS | Atai Therapeutics Inc. | 2024-09-05 | — | — | US | disclosed |
| WO-2024138032-A1 | DIMETHOXYPHENYL HETEROAROMATIC ALKYLAMINE ACTIVATORS OF SEROTONIN RECEPTORS | ENTHEOGENIX BIOSCIENCES, INC. (US) | 2024-06-27 | — | — | WO | disclosed |
| EP-4351548-A2 | DIMETHOXYPHENYLALKYLAMINE ACTIVATORS OF SEROTONIN RECEPTORS | ATAI Therapeutics, Inc. (US) | 2024-04-17 | — | — | EP | disclosed |
| US-11926574-B2 | Dimethoxyphenylalkylamine activators of serotonin receptors | Atai Therapeutics Inc. (US) | 2024-03-12 | — | — | US | disclosed |
| CN-117500487-A | Dimethoxy phenyl alkylamine activators of serotonin receptors | 恩泰奥吉尼克斯生物科学公司 | 2024-02-02 | — | — | CN | disclosed |
| US-11827580-B2 | Aminotetraline activators of serotonin receptors | ATAI Life Sciences AG (DE) | 2023-11-28 | — | — | US | disclosed |
| WO-2023129909-A1 | AMINOTETRALINE ACTIVATORS OF SEROTONIN RECEPTORS | ATAI Life Sciences AG (DE) | 2023-07-06 | — | — | WO | disclosed |
| US-20230202965-A1 | AMINOTETRALINE ACTIVATORS OF SEROTONIN RECEPTORS | ENTHEOGENIX BIOSCIENCES, INC. | 2023-06-29 | — | — | US | disclosed |
| US-20230138118-A1 | DIMETHOXYPHENYLALKYLAMINE ACTIVATORS OF SEROTONIN RECEPTORS | Atai Therapeutics Inc. | 2023-05-04 | — | — | US | disclosed |
| WO-2022261240-A2 | DIMETHOXYPHENYLALKYLAMINE ACTIVATORS OF SEROTONIN RECEPTORS | ATAI Life Sciences AG (DE) | 2022-12-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240300885-A1 | AMINOTETRALINE ACTIVATORS OF SEROTONIN RECEPTORS | HTR3B, HTR1B, TAAR5 | MPO 2764/4885HTR2A 9/4885HTR2C 30/4885 |
| US-11926574-B2 | Dimethoxyphenylalkylamine activators of serotonin receptors | HTR1A, HTR7, HTR4 | MPO 3360/4885HTR2A 12/4885HTR2C 8/4885 |
| US-20230138118-A1 | DIMETHOXYPHENYLALKYLAMINE ACTIVATORS OF SEROTONIN RECEPTORS | HTR1A, HTR7, HTR4 | MPO 3360/4885HTR2A 12/4885HTR2C 8/4885 |
| US-12351537-B2 | Dimethoxyphenylalkylamine activators of serotonin receptors | HTR1A, HTR7, HTR4 | MPO 3360/4885HTR2A 12/4885HTR2C 8/4885 |
| US-20250282708-A1 | AMINOTETRALINE ACTIVATORS OF SEROTONIN RECEPTORS | HTR3B, HTR1B, TAAR5 | MPO 2764/4885HTR2A 9/4885HTR2C 30/4885 |
| US-12344570-B2 | Aminotetraline activators of serotonin receptors | HTR3B, HTR1B, TAAR5 | MPO 2764/4885HTR2A 9/4885HTR2C 30/4885 |
| US-11827580-B2 | Aminotetraline activators of serotonin receptors | HTR3B, HTR1B, TAAR5 | MPO 2463/4885HTR2A 8/4885HTR2C 31/4885 |
| US-20250282712-A1 | DIMETHOXYPHENYLALKYLAMINE ACTIVATORS OF SEROTONIN RECEPTORS | HTR1A, HTR7, HTR4 | MPO 3360/4885HTR2A 12/4885HTR2C 8/4885 |
| US-20240294461-A1 | DIMETHOXYPHENYLALKYLAMINE ACTIVATORS OF SEROTONIN RECEPTORS | HTR1A, HTR7, HTR4 | MPO 3360/4885HTR2A 12/4885HTR2C 8/4885 |
| US-20230202965-A1 | AMINOTETRALINE ACTIVATORS OF SEROTONIN RECEPTORS | HTR3B, HTR1B, TAAR5 | MPO 2764/4885HTR2A 9/4885HTR2C 30/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.